Trial Profile
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Recordati
- 10 Jan 2024 this trial has been Completed in Bulgaria, According to European Clinical Trials Database record.
- 02 Mar 2022 Status changed from recruiting to completed.
- 06 Nov 2020 This trial is completed in Germany, according to European Clinical Trials Database record.